Description: ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Home Page: www.oricpharma.com
240 East Grand Avenue
South San Francisco,
CA
94080
United States
Phone:
650 388 5600
Officers
| Name | Title |
|---|---|
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman & Member of Scientific Advisory Board |
| Dr. Jacob M. Chacko M.B.A., M.D. | President, CEO & Director |
| Mr. Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer |
| Dr. Charles L. Sawyers B.A., M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Scott W. Lowe Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | General Counsel |
| Mr. Daniel Iazzetti | VP & Head of People |
| Dr. Edna Chow Maneval | Senior Vice President of Clinical Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4672 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 112 |